Key result
Study evaluates rivaroxaban in AMI with preexisting AF but reports no specific clinical outcomes.
Why the study?
Patients with AMI and preexisting AF have high rates of adverse events, but data on DOAC use in this group remain limited, particularly in Asian populations.
Does rivaroxaban improve clinical outcomes in patients with acute myocardial infarction and preexisting atrial fibrillation?
Cohort
Does rivaroxaban improve clinical outcomes in patients with acute myocardial infarction and preexisting atrial fibrillation?
Retrospective data on rivaroxaban in AMI with AF; leaves open comparative effectiveness and needs prospective confirmation.
Atrial fibrillation (AF), the most common arrhythmia, is correlated with elevated risk of myocardial infarction. Patients presenting with acute myocardial infarction (AMI) who have preexisting AF demonstrate higher rates of adverse events than those with new-onset AF [1]. However, in clinical practice, some patients exhibit suboptimal adherence and do not consistently receive anticoagulant therapy. Limited data are available regarding direct oral anticoagulant (DOAC) use among patients with AMI and preexisting AF, particularly in Asian populations. Recent real-world studies have demonstrated that rivaroxaban is the most frequently prescribed DOAC in China [2]. Therefore, we conducted a retrospective cohort study using the database from the Tianjin Health and Medical Big Data Super Platform to explore the association between rivaroxaban and clinical outcomes in patients with AMI and preexisting AF (Figure 1).
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) conducted a cohort in Acute myocardial infarction and preexisting atrial fibrillation. Rivaroxaban was evaluated on Clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: